關於戊型肝炎疫苗
A recombinant, 3-dose series HEV vaccine has been produced but has not yet been pre-qualified by WHO. The vaccine has been shown to prevent symptomatic HEV infection and proven to be safe and effective in people aged 16-64 years. Limited vaccine safety data in 37 pregnant women receiving 57 doses have been reported; however, further research is needed, and safety for children is unknown. The vaccine is expected to be protective against HEV genotype 1, the strain associated with most waterborne outbreaks in Africa and Asia.
